Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | SMYD2 | Q9NRG4 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL661651 | 0.91 | CYP3A4 (0.35) | CYP3A4HTTSMN1; SMN2SMYD2 | |
| SCHEMBL10102177 | 0.76 | SMYD2 (0.37) | CYP3A4HTTSMN1; SMN2SMYD2 | |
| SCHEMBL14042202 | 0.73 | FFAR1 (0.33) | — | |
| SCHEMBL661916 | 0.69 | REN (0.32) | — | |
| SCHEMBL30955759 | 0.67 | SMYD2 (0.43) | CYP3A4HTTSMN1; SMN2SMYD2 | |
| SCHEMBL30726327 | 0.67 | SMYD2 (0.43) | CYP3A4HTTSMN1; SMN2SMYD2 | |
| SCHEMBL30955729 | 0.67 | SMYD2 (0.43) | CYP3A4HTTSMN1; SMN2SMYD2 | |
| SCHEMBL28917486 | 0.64 | SMYD2 (0.43) | CYP3A4HTTSMN1; SMN2SMYD2 | |
| SCHEMBL31644559 | 0.64 | SMYD2 (0.41) | CYP3A4HTTSMN1; SMN2SMYD2 | |
| SCHEMBL31216593 | 0.64 | SMYD2 (0.41) | CYP3A4HTTSMN1; SMN2SMYD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8536157-B2 | Non-steroidal compounds | THE UNIVERSITY OF MELBOURNE (AU) | 2013-09-17 | — | — | US | disclosed |
| US-20120046255-A1 | NON-STEROIDAL COMPOUNDS | THE UNIVERSITY OF MELBOURNE of ROYAL PARADE PARKVILLE (AU) | 2012-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120046255-A1 | NON-STEROIDAL COMPOUNDS | PTGES2, PTGES, PTGES3 | CYP3A4 500/4885HTT 3412/4885SMN1; SMN2 3060/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.